Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma

Figures & data

Figure 1. Number of patients treated per year with carboplatin AUC 10.

Table I. Baseline characteristics.

Number of patients	61
Median age	38
Stage
IIA	15
IIB	13
IIC	14
IIIA	3
IIIB	16
Baseline tumour markers
LDH normal	22
LDH > normal < 1.5 × ULN	23
LDH > 1.5 × ULN	15
LDH result missing	1
βHCG normal	39
βHCG raised (>ULN –<5000)	21
βHCG > 5000	1
AFP normal	61

AFP, alphafetoprotein; βHCG, β human chorionic gonadotrophin; LDH, lactate dehydrogenase.

Figure 2. Kaplan-Meier curve for progression free survival.

Table II. Response of patients according to stage following treatment with single agent carboplatin.

Outcome	Stage at diagnosis^1
	Stage IIA N = 15	Stage IIB N = 13	Stage IIC N = 14	Stage IIIA N = 3	Stage IIIB N = 16	Total N = 61
Complete response	14 (93%)	9 (69%)	6 (43%)	1 (33%)	1 (6%)	31 (51%)
Marker negative partial response	1 (7%)	2 (15%)	8 (57%)*	2 (67%)	14 (88%)**	27 (44%)
Marker negative stable disease		2 (15%)				2 (3%)
Progressive disease					1 (6%)***	1 (2%)

CR, complete response – resolution of disease on imaging and normalisation of markers; M-PR, marker negative partial response – partial response on imaging but normalisation of markers; M-SD, marker negative stable disease – stable disease on imaging normal markers; PD, progressive disease, progression of disease on imaging and/or markers.

¹Disease staged according to the 2010 AJCC TMN classification; *1 patient relapsed 7 months after treatment, successfully treated with BEP chemotherapy; **1 patient relapsed within 4 months of treatment, successfully treated with BEP chemotherapy; ***Patient died 13 months after diagnosis.

Table III. Details of patients who relapsed following carboplatin treatment.

Age	Stage at diagnosis	Markers at diagnosis AFP/βHCG/LDH	Number of cycles of carboplatin	Response to carboplatin treatment	Time to relapse*	Further treatment	Current status
59	IIC	<3/<1/1346	4	M-PR	7 months	BEP	Progression free OS = 69.8 months
32	IIIB	<3/58/1611	4	M-PR	4 months	BEP	Progression free OS = 45.7 months
31	IIIB	3.5/2/295	4	PD	0 months	BEP	Died 13 months after diagnosis

BEP, bleomycin, etoposide and cisplatin chemotherapy; M-PR, marker negative partial response; OS, overall survival; PD, progressive disease.

*Time to relapse is from end of initial treatment to detection of relapse.

Figure 3. Blood products given per cycle of chemotherapy.

Table IV. Haematological toxicities (NCI Common Terminology Criteria for Adverse Events version V4.0).

Cycle number	Toxicity	Grade 1	Grade 2	Grade 3	Grade 4	Blood transfusion	Platelet transfusion	GCSF
Cycle 1	Neutropenia	13%	19%	35%	9%			22%
	Thrombocytopenia	39%	15%	11%	6%		0
	Anaemia	59%	11%	2%	0	2%
Cycle 2	Neutropenia	26%	19%	23%	21%			28%
	Thrombocytopenia	28%	15%	17%	15%		6%
	Anaemia	58%	30%	2%	0	4%
Cycle 3	Neutropenia	18%	16%	26%	4%			30%
	Thrombocytopenia	24%	20%	18%	4%		2%
	Anaemia	42%	36%	12%	4%	14%
Cycle 4	Neutropenia	28%	4%	12%	4%			40%
	Thrombocytopenia	16%	12%	12%	20%		4%
	Anaemia	20%	32%	32%	44%	40%